A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2017
At a glance
- Drugs MEDI 9314 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors MedImmune
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2016 Planned End Date changed from 1 May 2017 to 1 Jun 2017.